Compare Huntington Bancshares Incorporated (HBAN) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Bancshares Incorporated vs IDEXX Laboratories, Inc. — how do they compare? Huntington Bancshares Incorporated trades at $18.3 (market cap $36.83B), while IDEXX Laboratories, Inc. trades at $543.91 (market cap $43.58B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Huntington Bancshares Incorporated pays a 3.41% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HBAN | IDXX | |
|---|---|---|
Market Cap | $36.83B | $43.58B |
Sector | Financials | Health |
52-Week High | $19.27 | $766.68 |
52-Week Low | $15.02 | $526.44 |
Dividend Yield | 3.41% | — |
Enterprise Value | — | $44.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Huntington Bancshares (HBAN) trades at $18.17, down 0.44% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 13.9 and a net income margin of 25.13%, with Q2 2026 earnings expected at $0.39 per share. Recent news highlights the upcoming earnings report on July 23, 2026, and positive developments from the company's Texas expansion.
The outlook for HBAN is positive, driven by earnings growth potential and analyst consensus of $20.25 price target. Key risks include integration challenges from acquisitions and competitive pressures in regional banking markets. The stock presents a value opportunity with solid fundamentals, though investors should monitor expense management and loan growth trends.
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
